Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Radspherin
- Development stage
- Phase 2
- Lead developer
- Oncoinvent Solutions
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
**Radspherin** is an investigational, receptor-independent intraperitoneal alpha-radiopharmaceutical developed by Oncoinvent for eradication of residual microscopic peritoneal cancer after complete cytoreductive surgery. It consists of biodegradable calcium carbonate microparticles carrying the alpha-emitting radionuclide radium-224. After intraperitoneal instillation, the particles distribute across serosal peritoneal surfaces and deliver highly localized, short-range alpha radiation intended to destroy free-floating tumor cells and micrometastases while limiting irradiation of deeper normal tissues. Radspherin has completed early clinical studies in colorectal peritoneal metastases and recurrent ovarian cancer, and is being evaluated in a randomized Phase 2 study in homologous-recombination-proficient ovarian cancer with peritoneal metastases.
- Brand names
- Radspherin
- Other names
- radium-224-labelled calcium carbonate microparticlesradium224-labelled calcium carbonate microparticlesradium 224-labelled calcium carbonate microparticles224Ra-labelled calcium carbonate microparticles
02
Targets
MCAM
Beyond the preview
Go deeper on Radspherin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Radspherin.